Therefore, investigating the mechanisms, risk factors, prognostic implications, and optimal strategies for managing adverse effects arising from the concurrent T-DM1 with radiotherapy in HER-2-positive breast cancer will enable clinicians to better understand these interactions, implement interventions timely, and improve patient’s survival and quality of life ultimately. The gene discussed is ERBB2; the disease is breast cancer.